Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 90Neoplasms, Plasma Cell 28Central Nervous System Neoplasms 11Recurrence 10Glioblastoma 10Neoplasms 9Carcinoma, Hepatocellular 9Brain Neoplasms 9Gliosarcoma 8Melanoma 6Lung Neoplasms 6Leukemia 6Glioma 6Carcinoma, Non-Small-Cell Lung 6Waldenstrom Macroglobulinemia 5Prostatic Neoplasms 5Lymphoma, Mantle-Cell 5Myeloproliferative Disorders 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Immunoglobulin Light-chain Amyloidosis 4Colorectal Neoplasms 4Carcinoma, Renal Cell 4Astrocytoma 4Uveal Melanoma 3Oligodendroglioma 3Neuroblastoma 3Myelodysplastic-Myeloproliferative Diseases 3Myelodysplastic Syndromes 3Medulloblastoma 3

Interventions

Dexamethasone 8Bortezomib 7Cyclophosphamide 6Lenalidomide 4isatuximab 3glucarpidase 3Calcium Dobesilate 3Thalidomide 2Kidney Transplantation 2Blood Specimen Collection 2Bendamustine Hydrochloride 2pomalidomide 1gamma-Glutamyl Hydrolase 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1auricularum 1Whole-Body Irradiation 1Urination 1Urinalysis 1Stents 1Standard of Care 1Rituximab 1Ranitidine 1Nephrotomy 1Nephrostomy, Percutaneous 1Methotrexate 1Leucovorin 1Ice 1Hematologic Tests 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Renal Insufficiency × Thalidomide × Clear all
NCT04352205 2024-07-01

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

Emory University

Phase 2 Terminated
17 enrolled
Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT02424851 2022-01-27

OPTIMAL

Oxford University Hospitals NHS Trust

Phase 2 Completed
31 enrolled 13 charts
Plasma cell

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡